ClinicalTrials.gg
CompletedNCT04022096Updated Jan 27, 2023

Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis

A Phase 3 interventional study of Tegoprazan 25mg QD and Lansoprazole 15mg QD in Healed Erosive Esophagitis, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-27.

Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Esophagitis with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Esophagitis · Korea, Republic of.

Enrollment
4th of 12
351 · median 290
Started
2019
with 1 other
Phase 3
9 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
4 of 12
HK inno.N Corporation

Among the 12 studies in Esophagitis with a site in Korea, Republic of, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 3, and was the 8th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

None of the 12 studies in Esophagitis with a site in Korea, Republic of is open now. The open studies under Esophagitis, anywhere →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis with a site in Korea, Republic of as a file.
02

Study summary

This study is designed to confirm the non-inferiority of Tegoprazan 25mg, compared to Lansoprazole 15mg as maintenance therapy in patients with healed erosive esophagitis confirmed by endoscopy following oral administration once daily(QD) for 6 months.

Read the detailed description

This is a double blind, randomized, active-controlled, phase 3 study. Subjects will be randomly assigned to one of the two treatment groups (tegoprazan 25mg, lansoprazole 15mg).

03

Conditions studied

  • Healed Erosive Esophagitis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Erosive eshophagitis(LA classification Grades A to D) within 12 weeks prior to Randomization
  2. Healed erosive esophagitis within 7 days prior to Randomization
  3. No heartburn and regurgitation within 7 days prior to Randomization

Exclusion criteria

Exclusion Criteria:

  1. Unable to undergo upper GI endoscopy
  2. Presence of esophageal stricture, ulcerated stricture, gastroesophageal varix, long segment Barrett's esophagus with >3 cm length(LSBE), active digestive ulcer, gastric bleeding or malignant tumors on an upper GI endoscopy
  3. Diagnosed with primary esophageal motility disorder, irritable bowel syndome(IBS) or inflammatory bowel disease(IBD)
  4. History of acid-suppressive, esophageal or gastric surgeries
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    Tegoprazan 25mg QD

    Tegoprazan 25mg tablet, once daily, oral administration

    Drug: Tegoprazan 25mg QD

  • Active comparator
    Lansoprazole 15mg QD

    Lansoprazole 15mg capsule, once daily, oral administration

    Drug: Lansoprazole 15mg QD

Interventions

  • Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.

  • Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.

06

What researchers measure

Primary outcomes

  1. Endoscopic remission rate of EE at 24-week

    Endoscopic remission: No endoscopic recurrence of erosion(LA grade A to D) during maintenance period(24 weeks)

    Time frame: 24-week

Secondary outcomes

  1. Endoscopic remission rate of EE at 12-week

    Endoscopic remission: No endoscopic recurrence of erosion(LA grades A to D) during maintenance period(12 weeks)

    Time frame: 12-week

07

Study locations

1 site
  • Hanyang University Seoul Hospital
    Seoul, 133-792, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jun 2021, 24 months.

Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2019
First posted
Jul 16, 2019
StartActual
Jun 18, 2019
Primary completionActual
Jun 23, 2021
CompletionActual
Jun 23, 2021
Last update
Jan 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04022096
Responsible party
Sponsor
First posted
Jul 16, 2019
Start date
Jun 18, 2019
Primary completion
Jun 23, 2021
Completion
Jun 23, 2021
Last update
Jan 27, 2023

Study contacts

Oh Young Lee, Ph.D
principal investigator · Hanyang University Seoul Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion